The psoriasis clinical trials listed below are all phase 3 and recruiting participants as of July 19, 2022. For additional information on the study design, eligibility criteria, and contacts/locations, visit ClinicalTrials.gov.
GENERALIZED PUSTULAR PSORIASIS
Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis (GEMINI2)
ClinicalTrials.gov Identifier: NCT05366855
An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
ClinicalTrials.gov Identifier: NCT05200247
An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have No Other Treatment Options
ClinicalTrials.gov Identifier: NCT05239039
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP (GEMINI1)
ClinicalTrials.gov Identifier: NCT05352893
NAIL PSORIASIS
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
ClinicalTrials.gov Identifier: NCT03897075
PALMOPLANTAR PUSTULOSIS
Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
ClinicalTrials.gov Identifier: NCT05174065
PLAQUE PSORIASIS
A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov Identifier: NCT04175613
A Phase III Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov Identifier: NCT04839328
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
ClinicalTrials.gov Identifier: NCT04435600
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Adolescent Participants With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov Identifier: NCT04772079
Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults
ClinicalTrials.gov Identifier: NCT05203315
Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov Identifier: NCT04728360
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov Identifier: NCT05020249
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis (STELLAR-2)
ClinicalTrials.gov Identifier: NCT05335356
A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)(CIMcare)
ClinicalTrials.gov Identifier: NCT04123795
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
ClinicalTrials.gov Identifier: NCT03997786
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ClinicalTrials.gov Identifier: NCT05172726
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PROTOSTAR)
ClinicalTrials.gov Identifier: NCT03451851
PSORIATIC ARTHRITIS
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment (AgAIN)
ClinicalTrials.gov Identifier: NCT04632927
A Long-term Extension Study of Ustekinumab in Pediatric Participants (UNITED)
ClinicalTrials.gov Identifier: NCT05092269
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)
ClinicalTrials.gov Identifier: NCT05083182
Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis
ClinicalTrials.gov Identifier: NCT05046431
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ClinicalTrials.gov Identifier: NCT04991116
To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis
ClinicalTrials.gov Identifier: NCT04957550
PSORIATIC ARTHRITIS (continued)
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (SOLSTICE)
ClinicalTrials.gov Identifier: NCT04936308
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
ClinicalTrials.gov Identifier: NCT04908202
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
ClinicalTrials.gov Identifier: NCT04908189
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) ClinicalTrials.gov Identifier: NCT04882098 Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis (PEAPOD)
ClinicalTrials.gov Identifier: NCT04804553
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
ClinicalTrials.gov Identifier: NCT04610476
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
ClinicalTrials.gov Identifier: NCT04527380
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
ClinicalTrials.gov Identifier: NCT04314544
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti- TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
ClinicalTrials.gov Identifier: NCT04314531